DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Eva Smith, Final Year Medical Student, University of Dundee, Scotland. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. April 2019.
Chromosomes carry the genetic material of an organism (deoxyribonucleic acid, DNA). There are 23 pairs of chromosomes in human cells. These chromosomes carry all the genetic information for each cell to function properly.
Abnormalities in chromosomes can cause a variety of genetic disorders that can lead to developmental delay, congenital defects and abnormal bodily function .
These genetic diseases can be due to loss or gain of chromosomes or there are deletions or duplications of a chromosome. In these instances, the cell is missing specific genes and so cannot make certain proteins and carry out its function correctly. Examples relevant to dermatology include:
Cytogenetics is the study of chromosomes and their structure .
Cytogenetic testing involves analysis of cells in a sample of blood, tissue, amniotic fluid, bone marrow or cerebrovascular fluid to identify any changes in an individual’s chromosomes.
There are 3 major methods of cytogenetic testing.
Karyotyping was one of the first methods of chromosome analysis. This method uses light microscopy and standardised staining procedures on cells in the metaphase portion of the cell cycle when the chromosomes are most condensed .
To make the chromosomal analysis more effective and efficient, stains have been developed to bind with DNA and produce characteristic banding patterns to identify different chromosomes . The stain most commonly used is Giemsa dye . Through this process, the chromosomes can be organised into a karyogram of 23 pairs and any abnormality involving aneuploidy and large translocations can be identified.
Karyotyping can only identify changes over approximately 3 megabases . Any abnormality involving less than this will not be picked up by routine karyotyping. It can be used to identify Down syndrome and Turner syndrome.
Fluorescent in situ hybridisation (FISH) was first introduced in the late 1980s and has rapidly become a well-known diagnostic cytogenetic test in both congenital and acquired disease . FISH has a much higher resolution than routine karyotyping , especially when used on interphase cells .
FISH uses fluorescent probes with complementary base sequences to locate the presence or absence of specific portions of DNA on chromosomes [1,4]. The probe and target DNA must be denatured with heat or chemicals to break hydrogen bonds in the DNA and allow hybridisation to occur once the 2 samples are mixed . The fluorescent probes form new hydrogen bonds with their complementary base pairs on the DNA, and this can then be detected via microscopy .
FISH is commonly used to detect specific chromosomal deletions or translocations associated with paediatric conditions or cancers . Examples include the deletion on Chromosome 22 in DiGeorge syndrome and the translocation of part of a gene on chromosome 22 and 9 in chronic myeloid leukaemia .
Comparative genomic hybridisation (CGH) is a method of molecular cytogenetic testing that detects chromosomal copy number variants without the need for cell culturing . It was first developed to identify such changes in tumours [7,8].
CGH uses 2 genomes; the test sample and a control, both of which are fluorescently labelled to differentiate between the two . The two samples are denatured and mixed together, allowing hybridisation of metaphase chromosomes. The intensity of the fluorescent signal of the labelled test DNA relative to the control DNA can then be plotted along each chromosome, which shows loss or gain of genetic material and allows identification of any copy number variants .
CGH differs from other methods of cytogenetic testing in that it does not rely on a specific target, nor does it require previous knowledge of the region under examination . Instead, CGH can quickly scan a whole genome for these chromosomal imbalances  and is useful in cases where the diagnosis is not known. One limitation of CGH is the size of the genetic alteration that it can identify, the resolution of CGH is poor at approximately 5–10 megabases .
Microarray CGH utilises a similar technique as CGH but provides a much higher resolution by using microarrays . Small sections of DNA are used as targets for analysis; these sections are immobilised on solid support . As in CGH, the sample DNA and control are fluorescently labelled to differentiate them. The samples are then mixed and added to the microarray where they compete to bind to the probes on the microarray . The strength of the different fluorescent signals can be assessed and any small gains or losses within the DNA are identified. A disadvantage of microarray CHG is that it cannot detect balanced chromosomal structural changes such as balanced translocations or inversions .
Cytogenetic testing is used where a genetic abnormality is suspected.
Cytogenetic testing is performed on samples obtained in utero via amniocentesis or by chorionic villus sampling to identify a fetus with chromosomal abnormalities, such as Trisomy 21 in Down syndrome.
Cytogenetic testing is often used in paediatrics in an attempt to identify the underlying cause for developmental disorders or congenital defects. A diagnosis can be a huge relief to the families of affected children and will allow counselling regarding appropriate management and prognosis.
Cytogenetic testing is used in haematological cancers such as chronic myeloid leukaemia (CML) where a specific reciprocal translocation between chromosome 22 and 9 results in the Philadelphia chromosome, which is present in 95% of cases.
There are no medical contraindications to cytogenetic testing.
Informed consent should be obtained prior to arranging the tests.
Cytogenetic testing can offer diagnosis and help with long-term management of relevant diseases. It also allows genetic counselling for the parents about the risk in any future pregnancies and in some cases, guides the geneticist as to whether to test other family members.
Unfortunately, cytogenetic testing is limited by its resolution. The different methods can identify small gains and losses of genetic material, as well as larger translocations, but do not allow testing for single nucleotide variations that could contribute to the patient’s condition. There is also the possibility that cytogenetic testing will identify other chromosomal changes that are not necessarily related to the patient’s condition.
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.